Newsletter | August 25, 2022

08.25.22 -- How Automated, Closed Systems Can Improve Cell Manufacturing

 

With a continual need to increase reproducibility and decrease contamination — all while maintaining flexibility — the secret to improving cell manufacturing might just lie with automated, closed systems. Utilize the resources below in your journey toward improving cell manufacturing.

Enrichment Of Mononuclear Cells For CAR-T Cell Therapies
 

Enriching mononuclear cells (MNCs) by removing other cell types and contaminants is a critical step in CAR-T cell therapy production. This video explains why, how, and when you should carry out platelet depletion to achieve successful T cell enrichment.

CAR-T Cell Lentiviral Transduction By Spinoculation
 

There is a growing need to close and automate manufacturing of CAR-T cell therapies. Learn how to streamline this step while keeping flexibility during process development.

New Perfusion Filter Demonstrates Improved Cell Retention When Expanding Human T Cells In Xuri™ Cell Expansion System
 

A new 1.2 µm pore size filter was validated for use in the Xuri™ Cell Expansion System W25, which consists of a reusable instrument and single-use Cellbag™ bioreactors. The substantially smaller pore size of the new filter membrane decreased T cell loss, ultimately leading to higher T cell retention in the Xuri™ system Cellbag™ bioreactor.

Optimizing Recovery On The Sepax™ Cell Processing System
 

Performing dilution, concentration, and washing steps in a closed and automated manner is important in GMP cell therapy manufacturing. Using a model T cell line, we demonstrate the impact of varying rinse volume, intermediate volume, and manual extraction parameters on overall cell recovery with a final product dose volume of 20 mL.

Natural Killer Cells Manufacturing
 

Many studies are evaluating natural killer (NK) cells as potential cancer treatments. However, it is challenging to obtain primary NK cells at clinically relevant scale. Here, we generated 1 × 109 cells in a workflow amenable to a cGMP environment. Learn the workflow for xeno-free natural killer cell expansion from leukapheresis units. 

Closed And Semi-Automated Processing Of CAR T-Cells
 

This application note describes the details of a robust CAR-T cell manufacturing workflow that can be adapted for cGMP compliance in commercial production of CAR-T cells.

Secure and Standardize Your Manufacturing Process with Closed, Automated Systems

Contact Cytiva today to talk to a specialist about incorporating our automated cell processing and expansion technologies into your manufacturing workflow.